MAPK1 and cancer: RAS/MAPK pathway dysfunction is implicated in cancer, with somatic RAS drivers being responsible for ∼20% of malignancies (Bos, 1989) and hyperactivated ERK being found in a third of human cancers due to various other mutations associated with the pathway (Hoshino et al., 1999).